Table 1

Clinical findings in individuals who were diagnosed with mpox after having received the first dose of MVA

n (%)
Median days between MVA-BN and symptom onset (IQR)4 (3–9)
Median days between symptom onset and last sexual encounter (IQR)4 (3–6)
Sex partners in the 3 months prempox testing
 11/13 (8)
 79/13 (69)
 >63/13 (23)
Systemic symptoms11/15 (73)
 No prodromal symptoms6/15 (40)
 Fatigue/lethargy9/15 (60)
 Fever/chills8/15 (53)
 Myalgia4/15 (27)
 Sore throat4/15 (27)
Localised symptoms15/15 (100)
Number of skin lesions at peak
 1–1011/15 (73)
 11–251/15 (7)
 26–992/15 (13)
 >1001/15 (7)
Skin lesions distribution
 Genital (penis and/or pubic and/or scrotal)6/15 (40)
 Anal9/15 (60)
 Face/scalp6/15 (40)
 Torso6/15 (40)
 Limbs10/15 (67)
≥3 anatomical sites involved8/15 (53)
Mucosal involvement (oral and/or rectal)4/15 (27)
Lymphadenopathy9/15 (60)
Sexual health coinfections5/15 (33)
 HSV PCR test positive0/11 (0)
 Syphilis PCR test positive0/9 (0)
 Chlamydia trachomatis NAAT test positive5/15 (33)
 Neisseria gonorrhoeae NAAT test positive1/15 (7)
  • HSV, herpes simplex virus; mpox, monkeypox; MVA-BN, single dose of modified vaccinia Ankara; NAAT, Nucleic Acid Amplification Test.